India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
